A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048364

Enrollment

Unknown

Registered

2021-07-06

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castleman disease

Interventions

Treatment group:Rituximab+lenalidomide

Eligibility

Sex/Gender

All

Age

14 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Aged 14 to 90 years; 2.Meeting the diagnostic criteria of international consensus on Castleman disease; 3.Willingness to receive treatments and sign the informed consent form; 4.Able to comply with the scheduled follow-up visits and related procedures required in the protocol; 5.Life expectancy>= 12 weeks.

Exclusion criteria

Exclusion criteria: 1.Complicated with severe organ dysfunction, such as heart, lung, and liver failure; 2.Known active pulmonary tuberculosis or uncontrollable infection; 3.Known history of primary immunodeficiency diseases; 4.Regular examination and follow-up are not acceptable; 5.Pregnant or lactating female patients.

Design outcomes

Primary

Measure	Time frame
overall response rate;	—

Secondary

Measure	Time frame
progression-free survival;overall survival;	—

Countries

China

Contacts

Public ContactFan Lei

Department of Hematology, Jiangsu Provincial People's Hospital

fanlei3014@126.com+86 25 68306124

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026